Nexplanon (Etonogestrel)

Etonogestrel, the active ingredient in Nexplanon, is a progestin presented as a 68 mg subcutaneous implant for subcutaneous use. It provides continuous, long‑acting hormonal contraception to prevent pregnancy in women of reproductive age.

GNH USA supplies Nexplanon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution, including Europe, Asia, Africa and the Americas.

Etonogestrel, delivered via Nexplanon, acts within the hormonal contraceptive pathway to prevent pregnancy. - Contraception: provides long‑acting reversible contraception for women of reproductive age. - Birth control: delivers continuous progestin to suppress ovulation and maintain contraceptive efficacy for up to three years. - Prevention of pregnancy: offers a single‑implant solution that eliminates the need for daily dosing.

Etonogestrel may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Irregular bleeding or spotting - Amenorrhea (absence of periods) - Headache - Breast tenderness

Serious or Rare Side Effects: - Implant migration or extrusion - Infection at insertion site - Severe allergic reaction (anaphylaxis)

Prior to Nexplanon insertion, clinicians should assess several safety considerations to minimize risks. - Pregnancy testing: confirm the patient is not pregnant before implantation. - Breastfeeding: evaluate benefits and risks with a healthcare professional. - Medication interactions: review concomitant drugs that may reduce contraceptive efficacy. - Medical conditions: assess for liver disease, clotting disorders, or hormone‑sensitive cancers. - Smoking: advise cessation in women over 35 years who smoke. - Store at room temperature: keep the implant in its original packaging, protect from moisture and direct sunlight.

Etonogestrel’s contraceptive effectiveness can be altered by certain concomitant medications.

Major Interactions (Avoid): - Enzyme inducers (e.g., rifampin, carbamazepine, phenytoin): may markedly reduce hormone levels and increase risk of unintended pregnancy. - Antiretroviral protease inhibitors (e.g., ritonavir): can interfere with hormone metabolism.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., ketoconazole): may increase plasma concentrations of etonogestrel. - Certain antibiotics (e.g., ampicillin): have a minimal but possible effect on contraceptive reliability. - Herbal supplements (e.g., St. John’s wort, ginseng): may induce metabolic enzymes and affect hormone levels.